

**Anti-Complement component C1 inhibitor (human, C1INH)
Mouse monoclonal antibody**

 Subclass: IgG₁/k

PRODUCT NO.

HYB 288-05

Clone: 8 F3

PRESENTATION

Preparation: Protein-A/G purified

Content: Available in 200 µL and 1 mL volumes, 1 mg/mL

Solvent: 0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide

Storage: In the dark at 4-8°C

ANTIGEN

C1-inhibitor (C1INH) functions as a regulator of the activation of the classical complement pathway and of the contact activation system of kinin generation and coagulation. Its primary biologically relevant target proteinases are C1r, C1s, coagulation factors XIa and XIIa, and plasma kallikrein. C1-inhibitor consists of one polypeptide chain and has a molecular mass of 104 kDa (1,2). Serum concentration has been determined to 180 µg/ml (2).

IMMUNOGEN

C1-inhibitor (C1INH) isolated from human plasma adsorbed onto aluminum hydroxide gel

SPECIFICITY

HYB 288-05 is specific for human C1INH

EPI TOPE SPECIFICITY

Epitope specificity differs from that of HYB 288-02

REACTIVITY

HYB 288-05 reacts strongly with C1-INH. A strong reaction is seen with human serum/plasma when tested in sandwich ELISA in combination with a polyclonal antibody against C1-INH, and in ELISA with C1-INH coated directly onto the microtiter well.

CULTURE MEDIUM

RPMI 1640 with 10% fetal calf serum

FUSION PARTNER

SP2/O-Ag14

IMMUNIZATION

Female CF1 x BALB/c mice immunized by intraperitoneal injection

APPLICATION

Method	Usability	Dilution guideline	References
ELISA	Yes	1/16,000	
Immunoblotting	Not determined		
Immunohistochemistry	Not determined		

The dilution guideline for ELISA is based on sandwich ELISA in combination with a polyclonal antibody against the antigen. Users should determine the optimal dilutions for their own purpose.

REFERENCES

1. Law SKA, Reid KBM (1988) Complement. In: In Focus (Ed. Male D) IRL Press: Oxford.
2. Rasmussen JM (1991) Inherited deficiencies of complement proteins with special reference to congenital deficiency of the regulatory protein factor I. APMIS Suppl 22:1-48.
3. Bendtzen K et al (2000) Basal og klinisk immunologi. FADL's Forlag A/S, Copenhagen.
4. Bracho FA (2005) Hereditary angioedema. Curr Opin Hematol Nov12(6):493-98

CONDITIONS

All products are supplied on the understanding that they are for in vitro use only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The animals from which this product was derived have not been exposed to or inoculated with any livestock or poultry disease agents exotic to the United States or Western Europe, and did not originate from facilities where work with exotic disease agents affecting livestock or avian species is carried out.